Yang X S, Coupez R, Ector H, Kesteloot H, De Geest H
Department of Cardiology, University Hospital Gasthuisberg, Leuven, Belgium.
Acta Cardiol. 1987;42(4):273-86.
A randomized double-blind trial was performed with betaxolol, a beta 1-selective and long-acting beta-blocker, in patients with a recent first uncomplicated acute myocardial infarction (AMI). Patients were treated between the 3rd and 14th day after the onset of AMI with either a single oral dosage of 20 mg betaxolol or placebo. The effects on heart rate, ventricular and supraventricular arrhythmias were studied by continuous 24 hours ECG recordings on the 7th and between the 9th to 12th after the onset of AMI and by a submaximal exercise test on the 12th day. Hourly mean, peak and minimal heart rate were during the whole day significantly lower in the active treatment group. In betaxolol treated patients diurnal variations in heart rate were definitely changed. No differences in the occurrence of ventricular arrhythmias were found between both groups; auricular fibrillation was more common in placebo treated patients. Heart rate and pressure rate product were significantly higher during exercise in the placebo group. During exercise ventricular arrhythmias were infrequent in both groups. The clinical tolerance of betaxolol was excellent.
对近期首次发生无并发症急性心肌梗死(AMI)的患者进行了一项使用β1选择性长效β受体阻滞剂倍他洛尔的随机双盲试验。患者在AMI发病后第3天至第14天接受治疗,给予单次口服20mg倍他洛尔或安慰剂。通过在AMI发病后第7天以及第9天至第12天连续24小时心电图记录,以及在第12天进行次极量运动试验,研究对心率、室性和室上性心律失常的影响。活性治疗组全天的每小时平均心率、峰值心率和最低心率均显著较低。倍他洛尔治疗的患者心率的昼夜变化明显改变。两组之间室性心律失常的发生率无差异;安慰剂治疗的患者心房颤动更为常见。安慰剂组运动期间心率和压力心率乘积显著更高。运动期间两组室性心律失常均不常见。倍他洛尔的临床耐受性极佳。